Breaks Categories: News

TuesdayOct 13, 2020 11:20 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Platform Selected for Integration in Vitality’s Gateway Flex

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital-therapeutics market, today announced that Vitality Group has chosen the company's digital therapeutics solutions for inclusion in Vitality's new Gateway Flex offering. According to the update, Gateway Flex enables employers to personalize the health-care experience to meet the diverse and rapidly changing needs of their employees and allows employers to pay only for solutions in which their employees engage. “We believe that our inclusion in Vitality's Gateway Flex offering represents another recent validation of our digital therapeutic solution and reinforces our position as a partner of choice,” Rick Anderson, president and general…

Continue Reading

MondayOct 12, 2020 12:58 pm

BioMedNewsBreaks – Vivos Therapeutics Inc. Files Registration Statement for Proposed $20M Initial Public Offering

Vivos Therapeutics, a medical technology company that offers novel and proprietary alternatives for treating mild-to-moderate obstructive sleep apnea, on Friday announced that is has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of its common stock. According to the update, application has been made for listing the common stock on the Nasdaq Capital Market under the ticker symbol “VVOS.” The proposed $20,000,000 offering (not including the underwriters’ over-allotment option), which is subject to market conditions with no assurance as to its actual completion or terms, has…

Continue Reading

MondayOct 12, 2020 9:48 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights New Glioblastoma-Focused Segment Airing on Lifetime TV

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today highlighted a new segment from The Balancing Act titled, "Behind the Mystery," which will air on Lifetime TV and focus on glioblastoma. The segment, live this morning, follows the unique story of a glioblastoma patient and clinical insights regarding the rare and difficult-to-treat disease from Dr. Sigmund Hsu, a member of CNS Pharmaceuticals’ Scientific Advisory Board. In addition, a re-airing of the segment is planned for October 23, 2020. "It is encouraging to…

Continue Reading

FridayOct 09, 2020 12:11 pm

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Simply Wall St Article

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company focused on the development of drug products for patients with high unmet medical need conditions or no alternative treatment options, was featured in a Simply Wall St article. The piece highlights PCSA Co-Founder Patrick Lin’s recent stock purchase at near current price. The article reads, “Potential Processa Pharmaceuticals Inc. (NASDAQ: PCSA) shareholders may wish to note that the Co-Founder, Patrick Lin, recently bought US$125k worth of stock, paying US$4.00 for each share. While that's a very decent purchase to our minds, it was proportionally a bit modest, boosting their holding by just…

Continue Reading

FridayOct 09, 2020 11:42 am

BioMedNewsBreaks – Cardiff Oncology Inc. (NASDAQ: CRDF) Announces Pricing of Underwritten Public Offering

Cardiff Oncology (NASDAQ: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, recently announced the pricing of its previously announced underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $13.50 per share. Cardiff Oncology anticipates receipt of approximately $88 million in gross proceeds from the offering, which is expected to close on or about October 2, 2020, subject to the satisfaction of customary conditions. The company has granted the underwriters a 30-day option to purchase up to an additional 975,000 shares at…

Continue Reading

FridayOct 09, 2020 11:09 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Begins Manufacturing of Lead Drug Candidate in Europe

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that its European manufacturer, BSP Pharmaceuticals S.p.A. ("BSP"), has begun the manufacturing process for Berubicin Drug Product, its lead drug candidate for the treatment of glioblastoma multiforme (“GBM”). GBM is an aggressive form of brain cancer currently considered incurable. “Our preparations for filing an IND for Berubicin require continued execution in both our clinical and manufacturing initiatives,” CNS Pharmaceuticals CEO John Climaco said in the news release. “With the manufacturing of our…

Continue Reading

ThursdayOct 08, 2020 12:22 pm

BioMedNewsBreaks – CB Scientific Inc. (CBSC) Announces Thailand Launch of My-Cardia ECG Product Line, Services

CB Scientific (OTC: CBSC), engaged in providing innovative products and services for the ambulatory noninvasive cardiac monitoring space, today announced the targeted start of cardiac lab services operations in the country of Thailand through CBSC’s exclusive authorized distributor, Mango Wellness Co. Ltd. (“MWC”) and My Cardia Thailand Co. Ltd. (“MCT”), beginning Oct. 29, 2020. Under the agreement, MWC and MCT will be the exclusive distributor for CBSC’s proprietary FDA and CE-cleared EKG my-Cam Cardiac Event Monitor, the interactive cloud-based My-Cardia acquisition software, and the associated smartphone apps for both iOS and Android platforms in Thailand. The My-Cardia product line is…

Continue Reading

WednesdayOct 07, 2020 12:03 pm

BioMedNewsBreaks – Marizyme Inc. (MRZM) Closes Acquisition of Somahlution Inc., $7M Private Placement

Marizyme (OTC: MRZM), a client of Univest Securities LLC, a full-service investment bank and securities broker-dealer firm and a member of FINRA and SIPC, recently closed the acquisition of Somahlution Inc. and a private placement for $7,000,240 to which Univest Securities acted as the exclusive investment bank and sole-placement agent. According to the update, the Marizyme acquisition of Somahlution Inc. included all of Somahlution LLC’s assets including its DuraGraft(R) intellectual property, Somaceutica intellectual property and derivative works. In addition, Univest Securities raised a total of $7,000,240 in gross proceeds in a private placement offering with common shares only for Marizyme,…

Continue Reading

WednesdayOct 07, 2020 10:50 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) CEO Scheduled to Present at LD Micro Event

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, is slated to present at an upcoming LD Micro virtual event. GNPX’s Zoom presentation is scheduled for Wednesday, Oct. 14, at 11 a.m. ET. The presentation will feature Genprex president and CEO Rodney Varner, who will deliver a corporate presentation and then participate in a Q&A. Investors and others interested in viewing the presentation can register at https://ibn.fm/MiDEy. To view the full press release, visit https://ibn.fm/RdBSZ About Genprex Inc.  Genprex is a clinical-stage gene therapy company developing potentially life-changing technologies for patients…

Continue Reading

WednesdayOct 07, 2020 10:22 am

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Closing of Public Offering

Processa Pharmaceuticals (NASDAQ: PCSA) has closed its previously announced underwritten public offering of 4,800,000 shares of common stock, which were offered to the public for $4 per share. The clinical-stage biopharmaceutical company, which focuses on the development of drug products intended to provide treatment for and improve the survival and/or quality of life of patients who have a high unmet medical need condition or who have no alternative treatment, announced that the public offering resulted in gross proceeds of approximately $19.2 million. PCSA has filed a registration statement relating to the securities being sold with the Securities and Exchange Commission (“SEC”);…

Continue Reading